Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma

Publisher's Note: There is an Inside Blood Commentary on this article in this issue.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Blood 2017-09, Vol.130 (11), p.1375-1377
Hauptverfasser:	Connors, Joseph M., Ansell, Stephen M., Fanale, Michelle, Park, Steven I., Younes, Anas
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Antineoplastic Agents, Immunological - administration & dosage Antineoplastic Agents, Immunological - adverse effects Antineoplastic Agents, Immunological - pharmacology Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bleomycin - administration & dosage Bleomycin - adverse effects Brentuximab Vedotin Dacarbazine - administration & dosage Disease-Free Survival Doxorubicin - administration & dosage Drug Interactions Female Follow-Up Studies Hodgkin Disease - drug therapy Humans Immunoconjugates - administration & dosage Immunoconjugates - adverse effects Immunoconjugates - pharmacology Kaplan-Meier Estimate Letter to Lung Diseases - chemically induced Male Middle Aged Molecular Targeted Therapy Remission Induction Treatment Outcome Vinblastine - administration & dosage Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Publisher's Note: There is an Inside Blood Commentary on this article in this issue.
ISSN:	0006-4971 1528-0020
DOI:	10.1182/blood-2017-05-784678